Logo - springer
Slogan - springer

Biomedical Sciences - Cancer Research | Chinese Journal of Cancer

Cancer Communications

Cancer Communications

Editor-in-Chief: Rui-Hua Xu

ISSN: 2523-3548 (electronic version)

Journal no. 40880

BioMed Central

Open access BioMed Central
 Learn more about the metrics of this journal
  • Official journal of the Chinese Anti-Cancer Association and the US Chinese Anti-Cancer Association
  • Average time to first decision of 25 days
  • Waivers of publication costs offered for selected high quality articles

As a prestigious, international journal in the field of oncology, Cancer Communications publishes basic, clinical, and translational cancer research. It enjoys a large readership and is widely respected as the official journal of the Chinese Anti-Cancer Association and the US Chinese Anti-Cancer Association. With an average-time-to-first-decision after submission of just 25 days, the journal enables authors to comply with funder requirements on open access, and also waives the publication costs for selected, high quality articles. Cancer Communications is edited by an expert Editorial Board and a team of dedicated scientific editors.

Related subjects » Cancer Research - Oncology & Hematology

Impact Factor: 3.822 (2017) * 

Journal Citation Reports®

Abstracted/Indexed in 

Science Citation Index Expanded (SciSearch), Journal Citation Reports/Science Edition, Medline, PubMedCentral, SCOPUS, EMBASE, Google Scholar, BIOSIS, DOAJ, EBSCO Discovery Service, OCLC WorldCat Discovery Service, Pathway Studio, ProQuest-ExLibris Primo, ProQuest-ExLibris Summon, Reaxys

Read This journal on BioMed Central

For authors and editors

  • Journal Citation Reports®
    2017 Impact Factor
  • 3.822

Alerts for this journal


Get the table of contents of every new issue published in Cancer Communications.